News headlines about RXi Pharmaceuticals (NASDAQ:RXII) have been trending positive on Thursday, Accern Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. RXi Pharmaceuticals earned a news sentiment score of 0.26 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 45.3680239383947 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Here are some of the headlines that may have impacted Accern’s rankings:

RXi Pharmaceuticals (RXII) opened at $0.58 on Thursday. RXi Pharmaceuticals has a 12 month low of $0.32 and a 12 month high of $1.12.

RXi Pharmaceuticals (NASDAQ:RXII) last announced its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.11) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.11). During the same quarter in the previous year, the business posted ($0.34) EPS.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another publication, it was illegally copied and republished in violation of U.S. & international copyright law. The original version of this report can be read at https://www.thecerbatgem.com/2017/12/21/positive-press-coverage-somewhat-unlikely-to-impact-rxi-pharmaceuticals-rxii-share-price.html.

About RXi Pharmaceuticals

RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company’s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator.

Insider Buying and Selling by Quarter for RXi Pharmaceuticals (NASDAQ:RXII)

Receive News & Ratings for RXi Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.